Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 560 participants.

Also called NCT07129421

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 560 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07129421
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07129421. Randomized; single masking; primary purpose prevention. Start 2025-10-21 (anticipated); primary completion 2027-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR
Acronym
EMBLOK II
Condition
AORTIC VALVE DISEASES
Condition
Aortic Valve Stenosis and/or Insufficiency
Condition
Aortic Valve Regurgitation
Condition
Aortic Valve Replacement
Intervention (Device)
EMBLOK™ Embolic Protection System ("EMBLOK EPS")
Lead sponsor
Emblok, Inc. (class: industry)
Collaborator
Yale Cardiovascular Research Group (class: other)

Record details

Record id
cardio:ct-nct07129421
Content hash
b4f9a2cd202665bf9cf231eb4c481fe7d5c419a307d902d3e3b6b8518e24b93d